Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Tech provider Signant Health announced the acquisition of Ametris to unite its electronic clinical outcome assessments (eCOA) ...

A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the ...

Originally launched as Myeloid Therapeutics in 2021 by cell therapy pioneers Ronald Vale, Ph.D., and Siddhartha Mukherjee, ...

Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a win for a biotech that has struggled in recent months under the weight of a ...

Aptose Biosciences has scrapped a deal for a blood cancer drug candidate as part of its pending takeover by Hanmi ...

Humacyte was riding high in December 2024 when it secured an FDA green light for a groundbreaking implant. Now, as it looks ...

Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs.

Global contract research organization Icon has announced the opening of a new research facility in San Antonio, Texas, along ...

Three weeks after taking over as CEO of Lexicon Pharmaceuticals back in 2024, Michael Exton suggested the company close its ...

Takeda has ended development of its nausea and vomiting drug candidate for strategic reasons, continuing its multi-year ...

Boehringer Ingelheim has put up 407.5 million euros ($478 million) in biobucks to secure global rights to a first‑in‑class ...